Vasomotor symptoms and estrogen-progestogen therapy.
von Schoultz
B
B
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D004958:Estradiol / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016912:Levonorgestrel; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use; D009644:Norgestrel / Q000627:therapeutic use; D011374:Progesterone / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use*; D014666:Vasomotor System / Q000187:drug effects*
D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D011372:Progestins; D009644:Norgestrel; D004997:Ethinyl Estradiol; D011374:Progesterone; D004958:Estradiol; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D004964:Estriol; D008525:Medroxyprogesterone; D009640:Norethindrone